KLRS stock forecast, quote, news & analysis
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases... Show more
Kalaris Therapeutics (KLRS) Stock Analysis: TH103 Phase Progress Anchors a Modest Pullback
Key Takeaways
- Kalaris Therapeutics (KLRS) closed at $2.42 on November 6, 2026, a decline of roughly 3.2% from the $2.50 close recorded 30 calendar days earlier.
- The stock has been volatile within that window, sliding toward an intraday low near $1.78 in late October before recovering sharply into early November.
- The core investment thesis remains tied to TH103, an engineered anti-VEGF therapy being advanced through a Phase 1b/2 study in neovascular age-related macular degeneration (nAMD).
- Positive initial and expanded Phase 1a data, a strengthened cash position, and a consensus Buy rating from covering analysts have provided support even as the share price drifted lower.
- Preliminary Phase 1b/2 data is expected in the first half of 2027, with potential Phase 3 initiation targeted for year-end 2027.
- The company reported $93.5 million in cash, cash equivalents, and marketable securities as of June 30, 2026, expected to fund operations into the fourth quarter of 2027.
- For additional detail on valuation and catalysts, explore Kalaris Therapeutics Price Targets, Earnings, and Forecast pages.
- You can also explore Trending AI Robots to see how automated trading systems are positioned across the market.
Current Market Snapshot
Kalaris Therapeutics shares have traded in a modestly negative range over the past month, closing at $2.42 on November 6, 2026, versus $2.50 about 30 days earlier — a move of approximately -3.2%. The headline figure, however, understates the volatility beneath the surface. After holding near the $2.50 level in early October, the stock weakened through the middle of the month, touching an intraday low around $1.78 before staging a sharp rebound in the first week of November.
The stock remains well below the levels seen earlier in 2026 and reflects the broader pressure on clinical-stage, pre-revenue biotechnology names. With a market capitalization that has recently traded below its reported cash balance, the shares are being valued primarily on the long-term promise of TH103 rather than on near-term fundamentals. Liquidity is relatively thin, which can amplify day-to-day price swings in either direction.
Kalaris Therapeutics (KLRS) Business Overview and Competitive Position
Kalaris Therapeutics is a clinical-stage biopharmaceutical company headquartered in Berkeley Heights, New Jersey, focused on developing treatments for prevalent retinal diseases with significant unmet need. Its lead program, TH103, is a fully humanized recombinant fusion protein that acts as a decoy receptor against vascular endothelial growth factor (VEGF). The molecule was engineered for enhanced VEGF inhibition and extended intraocular retention, with the goal of enabling less frequent dosing than currently approved anti-VEGF therapies.
The company was founded by Dr. Napoleone Ferrara, whose pioneering research underpinned the broader anti-VEGF class of medicines used in ophthalmology. TH103 is currently in a Phase 1b/2 multiple-ascending-dose study in neovascular age-related macular degeneration, with plans to explore additional indications such as diabetic macular edema and retinal vein occlusion. Kalaris began trading on the Nasdaq Global Market in March 2025 following its business combination with AlloVir, Inc.
Recent Developments Driving KLRS
Several verified developments have shaped investor sentiment around Kalaris Therapeutics. In July 2026, the company reported positive Phase 1a data from expanded cohorts of treatment-naive nAMD patients, reinforcing the visual acuity, anatomical, and pharmacokinetic findings from its initial data release. The results supported the hypothesis that TH103's molecular design could translate into extended durability.
In August 2026, Kalaris reported second-quarter results, including a net loss of $11.5 million and $93.5 million in cash, cash equivalents, and marketable securities as of June 30, 2026. Management confirmed that patient dosing was ongoing in the Phase 1b/2 study and reiterated guidance for preliminary data in the first half of 2027. Around the same period, Morgan Stanley analyst Judah Frommer maintained an Overweight rating and a $14 price target, citing TH103's emerging clinical profile and a favorable risk-reward setup.
More recently, the stock's October decline and early-November recovery occurred against a backdrop of limited company-specific news, with a Schedule 13G filing disclosing a beneficial ownership position in late October. The rebound in early November coincided with positioning ahead of the company's next quarterly earnings report.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of automated trading systems from a broader universe of hundreds of AI-driven bots that monitor thousands of tickers. Only top-performing and most relevant robots are featured in this section, giving users a focused view of strategies that are currently drawing attention. These bots vary considerably in strategy, holding timeframe, and performance metrics, so the section is designed to help traders compare approaches rather than offer a single recommendation. Investors interested in systematic, data-driven market analysis can use the page as a starting point for evaluating how AI trading tools are being applied across equities, including the biotechnology sector.
2026 Outlook and What Investors Should Watch
Looking ahead, the primary drivers for Kalaris Therapeutics center on execution of the TH103 clinical program. Investors will be monitoring the pace of enrollment and dosing in the Phase 1b/2 study, with preliminary data expected in the first half of 2027 and potential Phase 3 initiation targeted for year-end 2027. Near-term attention is also focused on the company's quarterly earnings report, where management commentary on enrollment progress, manufacturing updates, and cash runway will be closely watched.
Broader risks include the inherent binary nature of clinical-stage drug development, competition from established anti-VEGF franchises and emerging longer-acting agents, and financing considerations as the company advances toward later-stage trials. Macroeconomic conditions and sentiment toward small-cap biotechnology names could also influence trading in the shares. As with any pre-revenue biotechnology company, outcomes depend heavily on future clinical data rather than current financial performance.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
KLRS's Stochastic Oscillator dives into oversold zone
The Stochastic Oscillator for KLRS moved into oversold territory on November 11, 2026. Be on the watch for the price uptrend or consolidation in the future. At that time, consider buying the stock or exploring call options.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where KLRS's RSI Oscillator exited the oversold zone, 33 of 41 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 80%.
The Moving Average Convergence Divergence (MACD) for KLRS just turned positive on October 28, 2026. Looking at past instances where KLRS's MACD turned positive, the stock continued to rise in 39 of 47 cases over the following month. The odds of a continued upward trend are 83%.
Following a +19.80% 3-day Advance, the price is estimated to grow further. Considering data from situations where KLRS advanced for three days, in 197 of 232 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 11, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on KLRS as a result. In 90 of 98 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where KLRS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
KLRS broke above its upper Bollinger Band on November 05, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for KLRS entered a downward trend on November 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 12 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 41 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.999) is normal, around the industry mean (3.498). P/E Ratio (-1.277) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 88 (best 1 - 100 worst), indicating slightly worse than average price growth. KLRS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. KLRS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology